Oncodesign Precision Medicine (STU:ZR8) Change In Working Capital : €0.00 Mil (TTM As of Jun. 2022)

View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Change In Working Capital?

Oncodesign Precision Medicine's change in working capital for the quarter that ended in Jun. 2022 was €0.00 Mil.

Oncodesign Precision Medicine's change in working capital for the fiscal year that ended in Dec. 2021 was €0.00 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Oncodesign Precision Medicine Change In Working Capital Historical Data

The historical data trend for Oncodesign Precision Medicine's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Change In Working Capital Chart

Oncodesign Precision Medicine Annual Data

Trend

Dec20

Dec21

Change In Working Capital

Oncodesign Precision Medicine Semi-Annual Data
	Dec20	Dec21	Jun22
Change In Working Capital	-	-	-

Oncodesign Precision Medicine Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Oncodesign Precision Medicine Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncodesign Precision Medicine (STU:ZR8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (STU:ZR8) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 rue Jean Mazen, Dijon, FRA, 21000

Website

https://www.opm.oncodesign.com

Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (STU:ZR8) Headlines

No Headlines